Terns Pharmaceuticals, Inc.
TERN
Peringkat dalam Saham
#3572
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Harga Saham
$52.95
Terakhir disinkronkan: 2026-05-15
Kapitalisasi Pasar
$4.77B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
529.61%
Negara
US
Perdagangan Terns Pharmaceuticals, Inc. (TERN)
Kategori
Healthcare
Laba untuk Terns Pharmaceuticals, Inc. (TERN)
Laba pada Dec 2025 TTM: $-95.63M
Menurut laporan keuangan terbaru dari Terns Pharmaceuticals, Inc., laba saat ini perusahaan adalah $-95.63M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-89.97M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-59.99M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Terns Pharmaceuticals, Inc. dari 2018 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-95.63M | 7.94% |
| 2024 | $-88.59M | -1.53% |
| 2023 | $-89.97M | 49.98% |
| 2022 | $-59.99M | 20.82% |
| 2021 | $-49.65M | 70.87% |
| 2020 | $-29.06M | -57.79% |
| 2019 | $-68.84M | 280.64% |
| 2018 | $-18.09M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -5,616.18% |
US
|
|
| $-3.09B | 3,128.20% |
US
|
|
| $-4.02B | 4,099.90% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,139.87% |
NL
|
